IR PRESENTATION January 2019
|
|
- Arnold Hodges
- 5 years ago
- Views:
Transcription
1 IR PRESENTATION January 2019
2 FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning of applicable securities laws, including, among others, statements concerning the Company s objectives and strategies to achieve those objectives, sales of the Company s products, the Company s product candidates and the timeline for their development and commercialization, the Company s future financial condition and performance, potential acquisition and licensing transactions, as well as other statements with respect to management s beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Such forward-looking information reflect management s current beliefs as of the date hereof and are based on information currently available to Management. Although the forward-looking information contained in these materials and to be discussed during this presentation is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking information is based on the Company s estimates and assumptions, and is subject to risks and uncertainties, that could cause actual results to differ materially from such forward-looking information, including those described in the Company s annual information form, management discussion and analysis and other documents filed with Canadian securities regulators, copies of which are available under the Company s profile at Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. 2
3 NON-IFRS MEASURES The Company reports its financial results in accordance with IFRS. However, we use certain non-ifrs financial measures to assess our Company's performance. We believe these to be useful to management, investors and other financial stakeholders in assessing Crescita's performance from both a financial and operational standpoint. The non-ifrs measure used in this presentation does not have any standardized meaning prescribed by IFRS and is therefore not comparable to similar measures presented by other issuers. This measure should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with IFRS found in our continuous disclosure documents. Adjusted EBITDA is a non-ifrs measure. This term is defined as earnings (loss) from continuing operations before interest, income taxes (recovery), depreciation and amortization, gain on debt renegotiations, net, equity-settled stock-based compensation (SBC), goodwill and intangible assets impairment, accretion on the fair value of inventory, and foreign currency (gains) and losses. Management believes that Adjusted EBITDA is an important measure of operating performance and cash flow and provides useful information to investors as it highlights trends in the underlying business that may not otherwise be apparent when relying solely on IFRS measures. 3
4 WHY INVEST 1 Company in turnaround and undervalued 2 Significant growth potential in Rx business proprietary formulations & 2 patented technologies 4 Multiple diversified revenue streams 5 Dermatology market expanding with higher demand for innovation 4
5 CRESCITA AT A GLANCE CRESCITA is a Canadian commercial dermatology company serving the prescription (Rx) & non-prescription (non-rx) markets 3 established skincare brands Strong pipeline of RX product candidates and cosmeceuticals is distributed by Taro Pharmaceuticals Inc. in the U.S. & by Galderma in ROW 2 patented technologies and 250+ proprietary formulations 50,000 sqf manufacturing facility offering CMO services and R&D capabilities Strong sector-specific management team 5
6 NON-RX SKINCARE PORTFOLIO Crescita owns and focuses on 3 brands Targeted skin conditions include aging and wrinkles, rosacea, acne and dry skin High quality, active ingredients Manufactured under Good Manufacturing Practice (GMP) 6
7 SALES & DISTRIBUTION FOOTPRINT Sales & Marketing Infrastructure in Canada Our Portfolio of non-rx skincare products are: Sold to healthcare professionals and professional aestheticians Distributed in aesthetics and medical clinics Sold by a highly trained sales force Supported by fully integrated marketing, training and customer service functions Available for export via distributors 7
8 PEEL AND DURAPEEL TM Topical and transdermal drug delivery Phase-changing cream using self-occlusion to deliver actives into or through the skin Proven capability with a variety of actives Reduced product transference risk Fast drying and extended drug delivery Latest patent expiring in 2027, for DuraPeel TM Peel Single-solvent system Currently used in Pliaglis DuraPeel Two solvent system (volatile and non-volatile) Volatile solvent evaporates resulting in flexible patch Flexible patch adheres to skin, maintaining drug delivery for desired application time Potential Dermatological Applications Acne Psoriasis Wound healing Anti-viral Anti-bacterial Warts Basal Cell Carcinoma (BCC) Rosacea 8
9 MMPE TM Topical and transdermal drug delivery MMPE Multiplexed Molecular Penetration Enhancer Description Uses synergistic combinations of pharmaceutical excipients Can be used for Rx and non-rx products Indication / Skincare actives Benefits Wrinkle reduction / anti-aging Firming of skin Exfoliation Moisturizing Increased penetration of API s Possible improved efficacy Skin lightening Acne Inflammation Lower API concentration Possible lower dosing Patent Status U.S. Patent until PCT applications pending - latest expiry in
10 RX PRODUCT The only FDA-approved, phase-changing, self-occluding topical anesthetic cream with the highest concentration of Tetracaine and Lidocaine Description API / Indication Topical local anaesthetic using our Peel technology Provides safe and effective local dermal analgesia on intact skin 7% Tetracaine + 7% Lidocaine Pain Patent Status Pliaglis until 2020 Flexicaine, 2 nd generation until 2031 Uses Dermal filler injections Pulsed-dye laser therapy Laser-assisted tattoo removal Non-ablative laser facial resurfacing Commercial Status Exclusive licensing agreement with Taro for U.S. rights signed in 2017 Pliaglis launched in U.S. in Q1-18 Galderma has ROW distribution rights. Crescita can reacquire starting in 2021 Potential for a further US$3.75 million in milestones 10
11 RX PRODUCT ROADMAP FORMULATION DEVELOPMENT/ PRE-CLINICAL IND FILED PHASE 1 PHASE 2 PHASE 3 COMMERCIAL Pliaglis U.S. Rights Out-Licensed to Taro (Crescita Rights - Canada, Mexico; Galderma - ROW) Flexicaine (2nd generation Pliaglis - Out-licensed to Taro) MiCal 1* (Topical treatment of Psoriasis) MiCal 2* ** Dermo Cosmetic Portfolio * Target development of 2 dermatological products. MiCal 1 is for treatment of Plaque Psoriasis. The therapeutic indication for MiCal 2 has not yet been disclosed. * Crescita responsible for formulation development / IP and providing MMPE technology * Fully funded by our partner Ferndale Laboratories and a leading U.S. CRO * Economic benefits to be shared upon out-licensing ** Dermo cosmetic portfolio internal development 11
12 CMO SERVICES Contract Manufacturing Organization Services FACILITY A modern, 50,000sqf Health Canada compliant manufacturing facility in Montreal, Canada MANUFACTURING CAPABILITIES Formulations manufactured by Crescita include: 1. Cosmetics products 2. Natural health products and 3. DIN (Drug Identification Number) products TURNKEY SOLUTIONS R&D and technology Needs analysis Ingredient sourcing Processing FORMULATIONS & PACKAGING We produce creams, liquids, gels, ointments & serums and package into tubes, bottles, vials and pumps Packaging Delivery 12
13 GLOBAL MARKET TRENDS Skincare market: ~US$180B by 2024 Cosmeceutical market: ~US$80B by 2023 Physician dispensed cosmeceuticals market: ~US $28B by 2024 Spa market: ~US$14B Canadians spend $1.4B in beauty products per year in 12,000 Spas in Canada, resort & medical spas, hotel, esthetics, day salons 13
14 CORPORATE STRATEGY & FOCUS Organic Growth International Markets & Out-Licensing Agreements Operational Effectiveness Innovation & Technology Strategic Acquisitions & In Licensing Agreements Contract Manufacturing Services (CMO) 14
15 DRIVING TRANSFORMATION 2019 & Beyond 2017 Out-licensed Pliaglis U.S. rights to Taro Acquired Alyria Completed $1.0M convertible debenture financing Paid down long-term debt by $4.2M 2018 Raised $3.5M through Rights Offering Announced U.S. launch of Pliaglis with $2.7M in YTD royalties Achieved 1st milestone on U.S. sales of Pliaglis, triggering payment of $1.3M 2018 cont d Reported 2 quarters of positive Adjusted EBITDA Reported improved penetration of CBD using MMPE and DuraPeel Launched 5 product innovations in skincare Reported FDA approval of Not for Home Use label restriction removal for Pliaglis Pursue transformational business development and operational activities 15
16 GEARED FOR GROWTH Rx Milestone Opportunities U.S. launch of Pliaglis by Taro US$0.5M milestone FDA approval of Not for Home Use label restriction removal Pliaglis launch in Canada Received $2.7M in Pliaglis royalties YTD + $1.3M sales milestone US$0.75M milestone U.S. Regulatory approval of Flexicaine MiCal 1 Completion of Phase 3 studies and potential out-licensing revenue z 2020 Focused on strategic M&A, international market and CMO expansion and organic growth 16
17 IMPROVING REVENUE & ADJ. EBITDA 17
18 FINANCIAL SNAPSHOT STOCK SYMBOL Market Cap (as at January 3, 2019 ) TSX: CTX $9.7M Share Price (as at January 3, 2019 ) $0.46 Shares Outstanding (as at January 3, 2019 ) 21.0M Fully Diluted Shares Outstanding (September 30, 2018 ) 24.9M Share Price 52-week Low-High $0.35 $0.90 Cash and Cash Equivalents (as at September 30, 2018 ) Non-Current Financial Liabilities (as at September 30, 2018 )* $8.2M $3.3M * Non-current financial liabilities are defined as the sum of the long-term portions of long-term debt, convertible debentures and other obligations. 18
19 WHAT S AHEAD
20 OUR STRATEGIC TARGET Strategic Aspiration to be a profitable $50M revenue-generating commercial dermatology company in 5 years
21 INVESTMENT HIGHLIGHTS Crescita represents an excellent investment opportunity: Undervalued and relatively new company Prescription products, led by Pliaglis in the U.S., represent significant upside potential Non-prescription business well positioned for international out licensing and growth in CMO business Multiple growing revenue streams Patented technologies can be leveraged in both Rx and non-rx business in many lucrative industries, such as Cannabis 21
22 TSX: CTX
IR PRESENTATION June 2018
IR PRESENTATION June 2018 FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning
More informationCrescita Therapeutics Inc. TSX: CTX
Crescita Therapeutics Inc. January 2018 Safe Harbour Certain information contained in these materials and to be discussed during this presentation constitute forwardlooking information within the meaning
More informationManagement s Discussion and Analysis (MD&A)
Management s Discussion and Analysis (MD&A) March 29, 2017 / The following information should be read in conjunction with the Crescita Therapeutics Inc. (Crescita or the Company) Consolidated Financial
More informationCrescita Therapeutics Inc. First Quarter Report 2017
Crescita Therapeutics Inc. First Quarter Report 2017 Management s Discussion and Analysis (MD&A) May 15, 2017 / The following information should be read in conjunction with the Crescita Therapeutics Inc.
More informationCrescita Therapeutics Inc. Third Quarter Report 2016
Crescita Therapeutics Inc. Third Quarter Report 2016 Management s Discussion and Analysis (MD&A) November 14, 2016 / The following information should be read in conjunction with the Crescita Therapeutics
More informationCrescita Therapeutics Inc. First Quarter Report 2016
Crescita Therapeutics Inc. First Quarter Report 2016 Management s Discussion and Analysis (MD&A) May 10, 2016 / The following information should be read in conjunction with the Crescita Therapeutics Inc.
More informationManagement s Discussion and Analysis (MD&A)
Management s Discussion and Analysis (MD&A) February 17, 2016 / The following information should be read in conjunction with the Nuvo Research Inc. (Nuvo or the Company) Consolidated Financial Statements
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 02/20/14 for the Period Ending 02/20/14 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationNuvo Research Inc. First Quarter Report 2015
Nuvo Research Inc. First Quarter Report 2015 Management s Discussion and Analysis (MD&A) May 12, 2015 / The following information should be read in conjunction with the Nuvo Research Inc. (Nuvo or the
More informationForward-looking Statements
MANAGEMENT S DISCUSSION AND ANALYSIS OF ACERUS PHARMACEUTICALS CORPORATION (FORMERLY TRIMEL PHARMACEUTICALS CORPORATION) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2015 The following management
More informationClick to edit Master title style. Annual and Special Meeting Of Shareholders. May 11, nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc.
Click to edit Master title style Annual and Special Meeting Of Shareholders May 11, 2017 nuvopharmaceuticals.com Nuvo Pharmaceuticals Inc. Click to edit Master title style Dan Chicoine Chairman Click Agenda
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationInvestor Relations Presentation. Delivering solutions, shaping the future
Investor Relations Presentation Delivering solutions, shaping the future Our Story Leader Differentiator Consistency Decades of experience Leading the dispensing solutions niche of the packaging industry
More informationFor personal use only
ASX/Media Release 30 August 2017 Botanix Pharmaceuticals Preliminary Final Report Highlights for the year ending 30 June 2017: Transformed single product company into rapidly growing medical dermatology
More informationInvestor Relations Presentation
Investor Relations Presentation Delivering solutions, shaping the future. Beauty + Home Food + Beverage Pharma Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking
More informationMANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2018 HLS
MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2018 HLS Therapeutics Inc. ( HLS or the Company ) was formed on March 12, 2018 by the amalgamation of HLS Therapeutics Inc. ( former
More informationTSX:LEAF Investor Presentation December 2017 Top Licensed Producer
TSX:LEAF Investor Presentation December 2017 Top Licensed Producer Price Close (Dec 7, 2017): $15.47 Market Capitalization: $1.5 billion Basic and F.D. Shares: 94.1/101.4 million Forward-Looking Information
More informationDELIVRA CORP. UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, AND (Expressed in Canadian Dollars) NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS
More informationEndo Health Solutions
Endo Health Solutions 3Q 2013 Earnings Report and A Compelling Combination: Endo Health Solutions and Paladin Labs November 5, 2013 Offer Language Disclosures This communication is not intended to and
More informationCYNAPSUS THERAPEUTICS INC.
CYNAPSUS THERAPEUTICS INC. Condensed Interim Consolidated Financial Statements For the Three Months Ended (Expressed in Canadian Dollars) Unaudited CYNAPSUS THERAPEUTICS INC. Page 2 Interim Consolidated
More informationAnika Therapeutics, Inc. Rodman & Renshaw 8 th Annual Healthcare Conference
Anika Therapeutics, Inc. Rodman & Renshaw 8 th Annual Healthcare Conference November 7, 2006 Safe Harbor Statement The statements made in this presentation which are not statements of historical fact are
More informationOBAGI MEDICAL PRODUCTS, INC. The Science of Transformation
OBAGI MEDICAL PRODUCTS, INC. The Science of Transformation ANNUAL REPORT 2007 OBAGI SYSTEMS MEETING THE NEEDS OF OUR PATIENTS Facial Aesthetic Systems Aesthetic patients who desire greater correction Obagi
More informationIntellipharmaceutics Announces First Quarter 2018 Results
April 16, 2018 Intellipharmaceutics Announces First Quarter 2018 Results TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationPhotocure ASA - Third Quarter Report 2008
Photocure ASA - Third Quarter Report 2008 Highlights Sales revenues increase 52% to NOK 23.6 million ( from NOK 15.6 million in third quarter 2007) Operating profit improved by NOK 13.7 million to NOK
More informationIn the third quarter of 2018, we continued to execute on our plans for expanding our business and reinforcing its growth potential.
Dear Nuvo Shareholders, In the third quarter of 2018, we continued to execute on our plans for expanding our business and reinforcing its growth potential. In the quarter, we announced the signing of definitive
More informationWuXi Biologics 2017 Interim Results
WuXi Biologics 2017 Interim Results August 2017 (Stock Code: 2269.HK) Forward-Looking Statements This presentation may contain certain forward-looking statements are not historical facts, but instead are
More informationMANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 HLS
MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 HLS Therapeutics Inc. ( HLS or the Company ) was formed on March 12, 2018 by the amalgamation of HLS Therapeutics
More informationDelivering Solutions. Shaping the Future.
Delivering Solutions. Shaping the Future. August 2014 Forward-Looking Statements This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationInvestor Presentation August 23, 2017
Investor Presentation August 23, 2017 Forward-Looking Information This Presentation contains forward-looking information within the meaning of applicable Canadian securities legislation which are based
More informationTSX:LEAF Investor Presentation October 2017
TSX:LEAF Investor Presentation October 2017 Price Close (Oct 6, 2017): $9.80 Market Capitalization: $890 million Basic and F.D. Shares: 90.8/93.2 million Forward-Looking Information This Presentation contains
More informationTecsys Reports Financial Results for the Third Quarter of Fiscal 2019
News Release FOR IMMEDIATE RELEASE Tecsys Reports Financial Results for the Third Quarter of Fiscal 2019 Second consecutive quarter of record bookings; strategic acquisitions expand market opportunities
More informationTSX:LEAF Investor Presentation March 2018
TSX:LEAF Investor Presentation March 2018 Price Close (Mar 16, 2018): $19.34 Market Capitalization: $1.9 billion Basic and F.D. Shares: 99.8/109.6 million Forward-Looking Information This Presentation
More informationFourth Quarter and Full Year 2017 Results. March 1, 2018
1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationInterim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY
Interim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY Press conference, May 21, 2013 at 10:00 a.m. (CET) Dial-in number: +46 8-50626900, enter code: 409017 Peter Wolpert, CEO and founder
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More informationASX Announcement MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE
23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE Revenue of $243.3m, a decrease of 17% on 1HFY17 Adjusted EBITDA of $70.2m, down 36% on 1HFY17 Reported EBITDA of $23.0m, down 82% on 1HFY17
More informationI n v e s t o r P r e s e n t a t i o n A c q u i s i t i o n o f C a n n a F a r m s
I n v e s t o r P r e s e n t a t i o n A c q u i s i t i o n o f C a n n a F a r m s July 30, 2018 TSX-V: VIVO OTCQB: ABCCF Disclaimer Certain information included in this presentation, which was prepared
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationIntellipharmaceutics Announces Second Quarter 2018 Results
July 16, 2018 Intellipharmaceutics Announces Second Quarter 2018 Results TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationMANAGEMENT S DISCUSSION AND ANALYSIS - FOR THE QUARTER AND THE SIX-MONTH PERIOD ENDED JANUARY 31, 2019.
Q2 2019 MANAGEMENT S DISCUSSION AND ANALYSIS - FOR THE QUARTER AND THE SIX-MONTH PERIOD ENDED JANUARY 31, 2019. 1. INTRODUCTION This Management s Discussion & Analysis provides the reader with an overview
More informationAMAG Pharmaceuticals. November 2015 A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS LIVES
Pharmaceuticals November 1100 Winter Street Waltham, MA 02451 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS LIVES All
More informationCANNASAT THERAPEUTICS INC.
CANNASAT THERAPEUTICS INC. For the year ended December 31, 2006 All amounts are expressed in Canadian (CDN) dollars unless otherwise indicated MANAGEMENT DISCUSSION AND ANALYSIS OF OPERATING RESULTS AND
More informationMoberg Derma AB (Publ) Interim report January - March
Moberg Derma AB (Publ) Interim report January - March CONTINUED STRONG GROWTH AND PROFITABILITY Launches have either already commenced or will start shortly in many European markets. The strong growth
More informationCELLMID LIMITED NOTES TO THE APPENDIX 4C
ASX ANNOUNCEMENT CELLMID LIMITED NOTES TO THE APPENDIX 4C Highlights for the quarter ending 31 March 2018: Record receipts from customers of $2.2 million, an increase of 81% in Q3 FY2018 compared with
More informationTHERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018
THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018 Montreal, Canada July 5, 2018 Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect
More informationBrilliance in photodynamic technology TM. Second quarter August 16th, 2007
Brilliance in photodynamic technology TM Second quarter 2007 August 16th, 2007 Total revenues increased 49% to MNOK 29.1 (19.5) Hexvix commercialisation gaining momentum Milestones payments of Euro 1.0
More informationTHERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017
THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017 Montreal, Canada February 7, 2018 Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Robert Abernathy Chairman and CEO
J.P. MORGAN HEALTHCARE CONFERENCE Robert Abernathy Chairman and CEO OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and conference call, including our 2016 outlook, expectations
More informationThird Quarter 2018 Review
Third Quarter 2018 Review November 2, 2018 Delivering solutions, shaping the future. Beauty + Home Food + Beverage Pharma Forward Looking Statements & Non-GAAP Financial Measures This presentation includes
More informationEndo International plc
Endo International plc Q2 2015 Earnings Report August 10, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationName: LAST FIRST MIDDLE INITIAL. Address: City: State: Zip: SSN: DOB: Age: Home Phone: Work Phone: Cell Phone: Occupation:
Today s Date: Name: LAST FIRST MIDDLE INITIAL City: State: Zip: SSN: DOB: Age: Home Phone: Work Phone: Cell Phone: Occupation: Mailing Address (if different): City: State: Zip: Primary Care Physician:
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationACTIVIST INVESTING RESEARCH
106 Yeakel Avenue Erdenheim, PA 19038 Damien J. Park President & CEO dpark@hedgerelations.com T: 215.325.0514 F: 215.392.4633 ACTIVIST INVESTING RESEARCH Company: Endo Pharmaceuticals Holdings, Inc. (ENDO)
More informationFor personal use only
Mayne Pharma Group Limited FY16 Results Presentation 26 August 2016 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO 1 Disclaimer The information provided is general in nature and is in
More informationValeant s Acquisition of Medicis: Creating a Global Leader in Dermatology September 4, 2012
Valeant Pharmaceuticals International, Inc. Valeant s Acquisition of Medicis: Creating a Global Leader in Dermatology September 4, 2012 Forward-Looking Statements This presentation contains forward-looking
More informationOBAGI MEDICAL PRODUCTS, INC.
OBAGI MEDICAL PRODUCTS, INC. FORM 10-K (Annual Report) Filed 03/13/09 for the Period Ending 12/31/08 Address 3760 KILROY AIRPORT WAY #500 LONG BEACH, CA, 90806 Telephone 562-628-1007 CIK 0001375247 SIC
More informationA Specialty Pharmaceutical Leader Focused in Pain and Neurology. Jefferies Global Healthcare Conference June 3, 2014
A Specialty Pharmaceutical Leader Focused in Pain and Neurology Jefferies Global Healthcare Conference June 3, 2014 Note on Forward-Looking Statements Statements made in this presentation that are not
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More informationCYNAPSUS THERAPEUTICS INC. (Formerly Cannasat Therapeutics Inc.)
CYNAPSUS THERAPEUTICS INC. (Formerly Cannasat Therapeutics Inc.) Condensed Interim Financial Statements For the Three Months Ended (Expressed in Canadian Dollars) Unaudited NOTICE OF NO AUDITOR REVIEW
More information2018 J.P. Morgan Healthcare Conference January 9, 2018
2018 J.P. Morgan Healthcare Conference January 9, 2018 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the
More informationInterim report January-June 2013 A DIFFERENT KIND OF PHARMA COMPANY
Interim report January-June 2013 A DIFFERENT KIND OF PHARMA COMPANY Telephone conference, August 6, 2013 at 10:30 a.m. (CET) Dial-in number: +46 8-506 26 900, enter code: 409017 Peter Wolpert, CEO and
More informationLannett Company, Inc. Kremers Urban Acquisition September 2, 2015
Lannett Company, Inc. Kremers Urban Acquisition September 2, 2015 Forward Looking Statements Except for historical facts, the statements in this presentation, as well as oral statements or other written
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More information(TSXV: LABS) MEDIPHARM LABS CORP. MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2018
(TSXV: LABS) MEDIPHARM LABS CORP. FOR THE YEAR ENDED DECEMBER 31, 2018 April 3, 2019 This management s discussion and analysis ( MD&A ) of the financial condition and performance of (the Company ) was
More informationSafe Harbor Statement
September 2018 Safe Harbor Statement Certain matters discussed in this presentation and oral statements made from time to time by representatives of the Company may constitute forward-looking statements
More informationJefferies Global Healthcare Conference. June 7, 2016
Jefferies Global Healthcare Conference June 7, 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationEndo Health Solutions
Endo Health Solutions 4Q 2013 Earnings Report and Announcing The New Endo February 28, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationQUARTERLYREPORT. SECOND QUARTER Ended June 30
2013 QUARTERLYREPORT SECOND QUARTER Ended June 30 MANAGEMENT S DISCUSSION AND ANALYSIS BELLUS Health Inc. (and its subsidiaries, including BHI Limited Partnership, together referred to as BELLUS Health
More informationCYNAPSUS THERAPEUTICS INC.
CYNAPSUS THERAPEUTICS INC. Condensed Interim Consolidated Financial Statements For the Three Months Ended (Expressed in Canadian Dollars) Unaudited NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationTheralase Technologies Inc. Interim Condensed Consolidated Financial Statements - Unaudited As at September 30, 2018 and for the nine-month periods
Theralase Technologies Inc. Interim Condensed Consolidated Financial Statements - Unaudited As at September 30, 2018 and for the nine-month periods ended September 30, 2018 and 2017 THERALASE TECHNOLOGIES
More informationSPECTRAL ANNOUNCES SECOND QUARTER RESULTS
SPECTRAL ANNOUNCES SECOND QUARTER RESULTS TORONTO, Canada August 14, 2018 Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by
More informationDelivering Shareholder Value. Investor Presentation Spring 2015
Delivering Shareholder Value Investor Presentation Spring 2015 Forward Looking Statement This presentation may contain forward-looking statements and predictions. These forward-looking statements, by their
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationInterim Financial Statements of (Unaudited) ACASTI PHARMA INC. Three month and nine month periods ended December 31, 2017 and November 30, 2016
Interim Financial Statements of ACASTI PHARMA INC. Three month and nine month periods ended and Interim Financial Statements Three month and nine month periods ended and Financial Statements Interim Statements
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationSinclair IS Pharma plc Investor Presentation. April 2012
Sinclair IS Pharma plc Investor Presentation April 2012 Disclaimer The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been
More informationPerrigo Fiscal Fourth Quarter Conference Call August 18, 2009
Perrigo Fiscal Fourth Quarter Conference Call August 18, 2009 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the
More informationSEPTEMBER QUARTERLY ACTIVITIES REPORT For Period Ended 30 September 2018
Algae Operations SEPTEMBER QUARTERLY ACTIVITIES REPORT For Period Ended 30 September 2018 Production o Atlanta Product Development facility operating at +100% of design capacity Production Improvements
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationQ MANAGEMENT S DISCUSSION AND ANALYSIS - FOR THE YEARS ENDED JULY 31, 2018 AND 2017 AND THE QUARTER ENDED JULY 31, 2018.
Q4 2018 MANAGEMENT S DISCUSSION AND ANALYSIS - FOR THE YEARS ENDED JULY 31, 2018 AND 2017 AND THE QUARTER ENDED JULY 31, 2018. 1. INTRODUCTION This Management s Discussion & Analysis provides the reader
More informationFor personal use only
ASX Release 23 April 2018 CannPal Animal Therapeutics Limited ACN: 612 791 518 ASX:CP1 CannPal 4C Quarterly Cash Flow Report Highlights for the quarter ending 31 March 2018 Secured all domestic and international
More informationFor personal use only
26 October 2018 ASX Code: MXC September 2018 Quarterly Activity Report Key milestones achieved towards MXC achieving its goal as a leading medicinal cannabis Bio-Pharma company GMP Certification and Manufacturing
More informationDr. Reddy s Q1 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationBUY Target: US$ Event. Impact. Action. Maintain BUY rating. Valuation
Flash Update 1 Palomar Medical Technologies PMTI : NASDAQ : US$12.87 BUY Target: US$16.25 Anup Mehta 1.847.864.1139 anup.mehta@canaccordadams.com William J. Plovanic, CFA 1.847.864.1137 william.plovanic@canaccordadams.com
More informationscr.zacks.com 111 North Canal Street, Chicago, IL UPDATE ZACKS ESTIMATES
Small-Cap Research January 18, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Cipher Pharmaceuticals Inc. (DND-TSX) DND: Expecting Strong
More informationAcquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma
NASDAQ: ACET ACETO Corporation Acquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma November 3, 2016 Disclosure This presentation contains forward-looking statements, as defined
More information36 th Annual J.P. Morgan Healthcare Conference. January 8, 2018
36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements
More informationDr Reddy s Laboratories Ltd. Q1 FY05 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 04 Branded Formulations
More informationAptarGroup Reports Record Fourth Quarter and Annual Earnings
FOR IMMEDIATE RELEASE AptarGroup Reports Record Fourth Quarter and Annual Earnings Crystal Lake, Illinois, February 9, 2017 -- (NYSE:ATR) today announced record fourth quarter and annual earnings for 2016.
More informationBAUSCH HEALTH COMPANIES INC. ANNOUNCES THIRD-QUARTER 2018 RESULTS
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES
More informationMcKesson Corporation J.P. Morgan Healthcare Conference
McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in
More informationFourth Quarter and Full Year End 2013 Financial Results Conference Call
Fourth Quarter and Full Year End 2013 Financial Results Conference Call February 27, 2014 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute
More information